Revolution Medicines, Inc.
daraxonrasib
metastatic pancreatic ductal adenocarcinoma
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for daraxonrasib in metastatic pancreatic ductal adenocarcinoma are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“On April 13, 2026, Revolution Medicines, Inc. (“Revolution Medicines”) announced positive Phase 3 results from the RASolute 302 trial for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in patients with metastatic pancreatic ductal”